APA (7th ed.) Citation

Jackson, G. H., Pawlyn, C., Cairns, D. A., Tute, R. M. d., Hockaday, A., Collett, C., . . . Group, U. N. H. C. S. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Jackson, Graham H., et al. Carfilzomib, Lenalidomide, Dexamethasone, and Cyclophosphamide (KRdc) as Induction Therapy for Transplant-eligible, Newly Diagnosed Multiple Myeloma Patients (Myeloma XI+): Interim Analysis of an Open-label Randomised Controlled Trial. Public Library of Science (PLoS).

MLA (9th ed.) Citation

Jackson, Graham H., et al. Carfilzomib, Lenalidomide, Dexamethasone, and Cyclophosphamide (KRdc) as Induction Therapy for Transplant-eligible, Newly Diagnosed Multiple Myeloma Patients (Myeloma XI+): Interim Analysis of an Open-label Randomised Controlled Trial. Public Library of Science (PLoS).